Nasdaq
$201.29▲ 0.58%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $79.87BShares out 400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
28- 10.16After-hours26.10.17 05:094Ownership#●●●
Moderna, Inc.
Moderna, Inc. President Stephen Hoge filed a Form 4 report regarding changes in his beneficial ownership of company securities on October 14, 2026. This filing serves as a routine disclosure of insider stock holdings.…more
$201.29+0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Regular26.10.15 23:32144Ownership
Moderna, Inc.
Stephen Hoge, an executive at Moderna, Inc., has filed an SEC Form 144 to report a plan for the sale of company shares. This is a standard filing disclosing an insider's intent to dispose of their holdings.…more
$201.29+0.58%vs prev closeView filingShare - 10.14Regular26.10.14 22:58144Ownership
Moderna, Inc.
Moderna, Inc. executive Stephen Hoge has filed an SEC Form 144 to report the proposed sale of company shares. This is a standard filing indicating an insider's plan to dispose of their holdings.…more
$201.29+0.58%vs prev closeView filingShare
27 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.23 04:05#●●●#●●●#●●●
Merck and Moderna Report Positive Phase 3 Results for mRNA Melanoma Therapy…more
Merck and Moderna announced that their investigational mRNA cancer therapy significantly reduced the risk of recurrence or death in melanoma patients during a Phase 3 trial. The companies are now engaging with regulatory authorities based on these positive clinical data.…more
$201.29+0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoRegular26.10.23 03:47
●●●●●●●● ●●●●● ●●●●●●
Moderna stock fell over 25% following an alleged leak of Phase 3 clinical data for its personalized melanoma vaccine, which suggested lower efficacy than previous studies. The market reacted negatively to concerns that the vaccine may offer less benefit than initially anticipated.…more
$201.29+0.58%vs prev closeShareBenzinga - 2d agoRegular26.10.23 02:20
●●●●●●●● ●●●●● ●●●●●●
Moderna's stock is facing downward pressure following an alleged leak of ESMO 2026 abstract data regarding its melanoma vaccine. The leaked data suggests a 42% reduction in recurrence or death risk for the Intismeran/Keytruda combination therapy.…more
$201.29+0.58%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report